Market Position MSB offers a unique CLIA- and CAP-accredited liquid biopsy solution combining CTC enumeration with CellSearch and comprehensive cfDNA/RNA profiling via MenariniSearch, presenting a differentiated package for oncology clinics and labs seeking minimally invasive tumor profiling.

Clinical Market Target opportunities include cancer centers and pathology labs that require standardized CTC enumeration and biomarker testing across solid tumors and multiple myeloma, with the potential to expand into other tumor types supported by NGS-based genomic profiling.

Technological Edge Leverage the integrated workflow of CTC analysis and AI-powered MenariniSearch genomic profiling to position MSB as a comprehensive liquid biopsy platform, enabling higher value tests, longitudinal monitoring, and actionable biomarker discovery.

Financial Fit Mid-sized biotechnology presence with substantial revenue and investor interest; potential partnerships or contract manufacturing for CLIA/CAP LDTs could scale testing volume while aligning with Menarini Group’s global footprint.

Strategic Partnerships Engage health systems, academic cancer centers, and diagnostic distributors to widen geographic reach, while highlighting regulatory compliance, pathologist oversight, and remote or centralized testing options to reduce operational barriers for adopters.